Vetoquinol: 2025 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)-- Regulatory News:

Vetoquinol (Paris: VETO) published its calendar of financial communication for 2025.

Next update: Annual Sales 2024, January 30th, 2025 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115886760/en/

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
[email protected]

Source: Vetoquinol

You May Also Be Interested In

• Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
• Beyond the Plains Safaris Expands Travel Advisor Program as Kenya Enters Landmark Year for U.S. Air Access
• TGS Vesting Under the 2023 Long-term Incentive Plan